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Background: MicroRNA-223 (miR-223) has been shown to be a potential diagnostic and prognostic
marker for several cancers. In addition, miR-223 has been reported to suppress osteosarcoma cell pro-
liferation in vitro. However, the clinical value of miR-223 is still unknown.
Methods: We detected the expression of miR-223 expression in the serum of osteosarcoma patients and
in osteosarcoma cancer cells using RT-PCR. We compared the serum expression of miR-223 with the
clinicopathological characteristics and survival of osteosarcoma patients. Finally, we explored the role of
miR-223 on the invasion of osteosarcoma cancer cells using cell migration and invasion assays.
Results: We observed that the expression of miR-223 was signiﬁcantly decreased in the serum of os-
teosarcoma patients and osteosarcoma cancer cells compared to healthy controls (Po0.01). Moreover, a
receiver operating characteristic (ROC) curve analysis indicated that serum miR-223 is a potential di-
agnostic marker of osteosarcoma with an area under the ROC curve (AUC) of 0.956. Importantly, the
patients with a lower expression of miR-223 tended to have distant metastasis (Po0.001) and a more
advanced clinical stage (Po0.001). In addition, the survival time of patients with low miR-223 expres-
sion was signiﬁcantly shorter compared to patients with high miR-223 expression (Po0.001). Further-
more, we found that miR-223 could inhibit the migration and invasion of osteosarcoma cells.
Conclusions: miR-223 might be related to the metastasis of osteosarcoma and could be used as a po-
tential diagnostic and prognostic biomarker in osteosarcoma.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma is one of the most common primary bone ma-
lignancies, with an incidence of 4–5 cases per million people,
mainly in adolescents and young adults [1]. Osteosarcoma loca-
lizes to the proximal tibia or the distal femur and has a highly
malignant tendency to destroy the surrounding normal tissues and
to metastasize [2,3]. Although there have been advancements in
treatment therapies, including chemotherapy, radiotherapy and
tumor excision strategies, it has been reported that approximately
50% of patients with osteosarcoma develop metastases, which
results in a low cure rate and a low 5-year survival rate [4].
Therefore, it is important to develop new strategies for the early
diagnosis of osteosarcoma to improve treatment strategies and the
prognostic outcomes in these patients. Although previous studies
have shown that some molecular targets are related to tumor-
igenesis, the molecular mechanism underlying osteosarcoma has
not been fully elucidated. Consequently, it is difﬁcult to developGmbH. This is an open access artstrategies for the effective diagnosis and prognosis of osteosarco-
ma [5,6]. Therefore, it is important to understand the molecular
mechanisms of osteosarcoma in order to identify novel diagnostic
and prognostic markers that will improve the clinical prognosis of
osteosarcoma patients.
MicroRNAs (miRNAs) are a class of small noncoding and en-
dogenous regulatory RNA molecules that are approximately 19–25
nucleotides in length [7,8]. Studies have shown that miRNAs reg-
ulate target gene expression by either inducing messenger RNA
(mRNA) degradation through perfect base-pairing or inhibiting
mRNA translation via imperfect base-pairing in the seed sequence
using the 3′-untranslated region (UTR) of target mRNAs [9,10].
Aberrant expression of miRNAs has been observed in human
cancers and has been shown to be involved in a variety of critical
cellular processes, including cell differentiation, proliferation and
metabolism [11]. In addition, the expression proﬁles of miRNAs in
plasma and serum samples have been used to accurately classify
human cancers, which suggest that miRNAs could potentially be
used as a diagnostic and prognostic marker of cancer [12]. Mi-
croRNA-223 (miR-223) is a hematopoietic speciﬁc microRNA with
crucial functions in myeloid lineage development [13]. Previousicle under the CC BY-NC-ND license
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cancers, such as hepatocellular carcinoma, acute lymphoblastic
leukemia, gastric MALT lymphoma and recurrent ovarian cancer
[14–17]. Recently, Xu et al. [18] demonstrated that miR-223 was a
tumor suppresser in osteosarcoma and showed that miR-223/Ect2/
p21 signaling played a role in osteosarcoma cell cycle progression
and proliferation. However, the role of miR-223 expression in the
diagnosis and prognosis of osteosarcoma has not been reported.
In the present study, we detected the expression of miR-223 in
the serum of osteosarcoma patients and osteosarcoma cancer cells
using RT-PCR. In addition, we analyzed the role of miR-223 in the
diagnosis and prognosis of osteosarcoma. Moreover, we in-
vestigated the potential role of miR-223 in osteosarcoma
metastasis.2. Materials and methods
2.1. Patients and specimens
We collected the serum samples from 112 osteosarcoma pa-
tients who were recruited from the Department of Pathology at
The First Afﬁliated Hospital of Zhengzhou University, from 2008 to
2011. None of the patients had received chemotherapy or radiation
therapy prior to the surgery. The clinical stage of the osteosarcoma
patients was classiﬁed according to the Tumor Node Metastasis
(TNM) Classiﬁcation of Malignant Tumors (Sixth edition) from the
Union for International Cancer Control (UICC) [19]. All of the os-
teosarcoma patients received routine follow-up after surgery
(every 4 months) until their death or the last follow-up period. The
serum samples from the osteosarcoma patients and healthy con-
trols were collected prior to surgery and then frozen and stored at
80 °C for RNA extraction.
2.2. Cell lines and cell culture
Osteosarcoma cancer cell lines (U2OS, HOS, MG-63) and the
conditionally immortalized human fetal osteoblastic cell line hFOB
were purchased from American Type Culture Collection. The U2OS,
HOS and MG-63 cells were cultured in Dulbecco's Modiﬁed Eagle
Medium (DMEM) supplemented with fetal bovine serum in a
humid atmosphere with 5% CO2 at 37 °C. The hFOB1.19 cells were
maintained in a 1:1 mixture of Ham's F12 Medium and Dulbecco's
Modiﬁed Eagle's Medium supplemented with 2.5 mL of glutamine
(without phenol red) and 10% fetal bovine serum.
2.3. Quantitative real-time polymerase chain reaction (qRT-PCR)
The serum levels of miR-223 in the osteosarcoma patients and
healthy controls were detected using qRT-PCR assay. RNA extrac-
tion was performed using a mirVana PARIS kit (Ambion, Austin,
TX) according to the manufacturer's instructions. Reverse tran-
scription (RT) was performed with a total of 10 ng of total RNA
using a TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) according to the manufacturer's
instructions. The sequences of the primers were as follows: miR-
223 forward, 5′-AGC CGT GTCAGTTTG TCA AAT-3′; reverse, 5′-
GTGCAGGGTCCGAGG TC-3′ U6 forward 5′-CTCGCTTCG GCAGCA
CA-3′ and reverse 5′-AACGCTTCACGA ATTTGCGT-3′. U6 sRNA was
used as internal control. Real-time PCR reactions for miRNAs were
performed using the TaqMan MicroRNA PCR Kit (Applied Biosys-
tems, Foster City, CA, USA), and the ﬂuorescent data from each
sample was transformed using the 7500 SDS System software
(Applied Biosystems, Foster City, CA, USA). The 2ΔΔCt method
was used to calculate the quantity of miR-223. Each sample was
examined in triplicate, and the relative expression level of miR-223 was normalized to the expression of U6 using the 2△△Ct cycle
threshold method. The expression level of the target gene in the
osteosarcoma patients and cancer cell lines is expressed as per-
centage relative to the expression level in healthy controls and the
normal cell line, hFOB1.19 (normalized to 1).
2.4. Overexpression of miR-223 mimics and cell migration and in-
vasion assays
miR-223 mimics were designed as pre-miR miRNA precursor
(hsa-miR-223–3p; P⁄N: AM12301; Applied Biosystems). The nega-
tive control RNA duplex consisted of non-speciﬁc sequences that
are nonhomologous to any human genome sequences. The RNAs
were incubated with Opti-MEM (Invitrogen) and Lipofectamine
RNAiMAX transfection reagent. The cell transwell invasion assay
was performed using 24-well transwell plates (8.0 mm, BD Bio-
Coat). The HOS and MG-63 cells were transfected with miR-223
mimics and incubated for 24 h. We added 5104 cells in serum-
free media to the upper chamber and ﬁlled the transwell chamber
with 750 ml of 10% fetal bovine serum and then incubated at 37 °C
for 24 h. The cells on top of the upper chamber were removed
using a cotton-tipped swab. The cells on the membrane were
stained for 5 min using crystal violet, and then, microscopic ima-
ges were taken of 5 randomly selected ﬁelds. The relative cell in-
vasion rate (%) was calculated as the number of cells in the
treatment group/control group100%. For the wound closure
assay, HOS and MG-63 cells were plated onto 6-well plates and
transfected with miR-223 mimics. The cells were cultured until
they formed a 100% conﬂuent monolayer. Then, the monolayer
cells were scratched to form a 100 mm “wound” using a sterile
pipette tip. The cells were incubated for an additional 24 h. The
migration area was calculated as the wound area at T0 mins the
wound area after 24 h.
2.5. Statistical analysis
Statistical analyses were performed using SPSS Software (ver-
sion 18.0) and GraphPad Software. The Mann Whitney U test was
used to compare the differences in the serum levels of miR-223
between the osteosarcoma patients and the healthy controls. The
receiver operating characteristic (ROC) curve was drawn to eval-
uate the diagnostic value of the serum miR-223 levels. The Chi-
squared test was used to assess the relationship between the miR-
223 expression and the clinicopathological features. The Kaplan–
Meier method and log-rank test were used for the survival ana-
lysis. Statistical signiﬁcance in this study was set at Po0.05.3. Results
3.1. The expression of miR-223 and its diagnostic value in
osteosarcoma
The serum expression level of miR-223 was examined in 112
osteosarcoma patients and 50 healthy controls using qRT-PCR. As
shown in Fig. 1(A), we observed signiﬁcantly lower expression of
miR-223 in the osteosarcoma patients (1.2170.13) compared to
the healthy controls (3.970.34, Po0.01). Moreover, Fig. 1
(B) shows that the expression of miR-223 was signiﬁcantly down-
regulated in the osteosarcoma cell lines (U2OS, HOS and MG-63)
compared to the hFOB control cell line. Fig. 1(C) shows the ROC
curve analysis and indicates that serum miR-223 levels might be a
potential biomarker for distinguishing osteosarcoma patients from
healthy controls; AUC was 0.926. When the cut-off value was set to
1.76 according to Youdex, the sensitivity and speciﬁcity of dis-
criminating miR-223 in osteosarcoma patients was 89.5% and
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Fig. 1. (A) The serum expression levels of miR-223 in osteosarcoma patients (1.2170.13) were signiﬁcantly lower compared to the healthy controls (3.970.34, Po0.01).
(B) Decreased expression of miR-223 was found in three osteosarcoma cell lines (U2OS 0.8070.12, HOS 0.5770.26 and MG-63 0.2570.19) compared to a control cell line
(hFOB 1.070.01). (C) ROC analysis showed that serum miR-223 levels could distinguish osteosarcoma patients from healthy controls (AUC¼0.956).
Table 1
Association between serum miR-223 expression and clinical parameters in osteo-
sarcoma patients.
Parameters No. of cases miR-223-high (n) miR-223-low (n) P
Gender 0.455
Male 55 27 28
Female 57 32 25
Age 0.664
o18 60 31 29
Z18 52 28 24
Tumor site 0.111
Femur/Tibia 65 30 35
Others 47 29 18
Tumor size 0.792
o8 cm 63 35 28
Z8 cm 59 24 25
Clinical stage o0.001
IIA 72 50 22
IIB/III 50 10 40
Metastasis o0.001
Absent 87 56 31
Present 25 3 22
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3.2. Decreased expression of serum miR-223 is associated with
clinicopathological characteristics in patients
We performed a preliminary analysis to identify whether ser-
um miR-223 expression was associated with clinicopathological
parameters in patients with osteosarcoma. The patients were di-
vided into high and low miR-223 expression according to the
median value of serum miR-223 expression (1.21). The results
showed that low miR-223 expression occurred more frequently in
osteosarcoma patients with distant metastasis (Po0.001) and
advanced clinical stage (Po0.001). However, there was no sig-
niﬁcant association between serum miR-223 expression and age,
gender, tumor site or tumor size in the osteosarcoma patients
(P40.05) (Table 1).
3.3. Prognostic value of serum miR-223 in osteosarcoma patients
A Kaplan-Meier curve was performed to further assess the
prognostic value of serum miR-223 expression for osteosarcoma
patients. As shown in Fig. 2, the patients with low serum miR-223
expression had a shorter survival time compared to the patients
with high serum miR-223 expression (Po0.001). A multivariate
Cox regression analysis was performed to determine whether
serum miR-223 expression could be used as an efﬁcient prognostic
marker for the survival of patients with osteosarcoma. The resultsshowed that serum miR-223 expression (RR¼4.59, 95% CI 1.84–
11.45, P¼0.001), clinical stage (RR¼2.80, 95% CI 1.25–6.27,
P¼0.01) and distant metastasis (RR¼2.11, 95% CI 1.02–4.36,
P¼0.04) were independent prognostic factors for overall survival
of osteosarcoma patients (Table 2).
Fig. 2. A Kaplan–Meier survival curve showed the relationship between the overall
survival of osteosarcoma patients and the serum miR-223 levels.
Table 2
Multivariate survival analyses for prognostic factors in osteosarcoma patients.
Variables R Hazard ratio value 95% CI P
MiR-223 4.59 1.84–11.45 0.001
Clinical stage 2.80 1.25–6.27 0.01
Metastasis 2.11 1.02–4.36 0.04
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cells
We used a wound closure assay and transwell invasion assay to
assess the potential role of miR-223 in osteosarcoma cancer me-
tastasis. As shown in Fig. 3, the migration and invasion of the HOS
and MG-63 cells that overexpressed miR-223 was inhibited com-
pared to the negative control and native cells (Po0.05 and
Po0.001, respectively).4. Discussion
Osteosarcoma derives from primitive bone-forming mesench-
ymal cells and is the most common type of primary bone malig-
nancy [20]. Over the past few decades, the introduction of com-
binatorial chemotherapy has improved the 5-year overall survival
rate of patients with osteosarcoma to approximately 50–60% [21].
However, osteosarcoma-related morbidity remains high due to the
difﬁculty of early diagnosis and the lack of efﬁcient therapeutic
approaches for osteosarcoma. Therefore, it is necessary to identify
highly sensitive and speciﬁc diagnostic and prognostic biomarkers
to diagnose osteosarcoma at an early stage and initiate aggressive
therapy.
Studies have shown that miR-223 has a crucial role in cancer
development. Additionally, miR-223 abnormal expression was
found in several cancer types [22,23]. More importantly, serum
miRNA expression has been shown to be a promising candidate for
early detection and prognosis in cancer patients [24]. A recent
study showed that miR-223 is involved in osteosarcoma cell cycle
progression and proliferation [18]. However, the role of miR-223 as
a serum diagnostic and prognostic biomarker has not been pre-
viously explored in osteosarcoma patients. In the present study,
we quantiﬁed the serum expression levels of miR-223 in osteo-
sarcoma patients and healthy controls and then assessed the po-
tential value of miR-223 as a serum diagnostic and prognostic
marker in osteosarcoma patients.
The results from our study show for the ﬁrst time that the
expression of miR-223 was remarkably decreased in the serum of
osteosarcoma patients and in osteosarcoma cancer cell lines.Furthermore, we showed that the expression of miR-233 could be
used to discriminate osteosarcoma from healthy controls
(AUC¼0.962), with a speciﬁcity of 86.4% and a sensitivity 97.2%.
Notably, decreased serum miR-223 levels were found to be sig-
niﬁcantly associated with distant cancer metastasis and advanced
clinical stage in osteosarcoma patients, which suggests that miR-
223 might act as a tumor suppressor in the development of os-
teosarcoma. This ﬁnding is consistent with previous ﬁndings that
miR-223 could inhibit osteosarcoma cell cycle progression and
proliferation [18]. miRNAs can act as oncogenes or tumor sup-
pressor in multiple types of cancers when abnormally expressed
[25]. Similar to other miRNAs, the expression and role of miR-223
signiﬁcantly varies in different types of cancer. Previous studies
have shown that miR-223 is signiﬁcantly downregulated in cancer
tissues of patients with prostate cancer, suggesting that miR-223
may act as a tumor suppressor in prostate cancer [26]. Conversely,
miR-223 has also been reported to be overexpressed in other types
of cancers, such as esophageal carcinoma and gastric cancer
[27,28]. Predicting the clinical outcomes of osteosarcoma patients
is important for better treatment and therapeutic strategies. Pre-
vious studies have found that the abnormal expression of miR-223
was associated with the development and prognosis of lymphoma
[29]. In the present study, we assessed the prognostic role of miR-
223 in patients with osteosarcoma and showed that serum miR-
221 is a potential independent and effective prognostic biomarker
for osteosarcoma, particularly for patients with advanced clinical
stage and distant metastasis. In addition, the transwell invasion
assay showed that miR-223 mimics signiﬁcantly inhibited the in-
vasion of MG-63 cells, which suggests that miR-223 may play a
role in osteosarcoma metastasis.
Previous studies have shown that miR-223/epithelial cell
transforming sequence 2 (Ect2) signaling might be an important
pathway regulating cell cycle progression and proliferation in os-
teosarcoma. Moreover, miR-223/Ect2 signaling was shown to be
correlated with the recurrence and the poor response to che-
motherapy in osteosarcoma [30]. In addition, inhibition of miR-
223 expression promotes osteosarcoma cell proliferation by tar-
geting Ect2 activation [31]. Furthermore, Ect2 expression is ele-
vated in various tumor cell lines and tissues, including lung cancer,
esophageal cancer, pancreatic cancer and oral cancer, which sug-
gests that Ect2 may function as a proto-oncogene [32,33]. There-
fore, we speculated that miR-223 may inhibit cell invasion by
negatively regulating Ect2 expression during the progression of
osteosarcoma. Future studies are necessary to determine the
downstream functional targets of miR-223 in osteosarcoma. The
results of the present study and other similar studies suggest that
miR-223 is a potential biomarker in cancer development. How-
ever, it should be noted that all of these studies were collected in
one center with relatively small number of samples. Therefore,
future studies with a larger sample size are necessary to conﬁrm
these results.
In conclusion, decreased miR-223 expression was associated
with advanced clinical stage and distant metastasis in osteo-
sarcoma patients, which suggests that miR-223 has a suppressive
role in osteosarcoma. In addition, we showed that miR-223 might
be a potential diagnostic and prognostic marker in osteosarcoma.
Most importantly, decreased miR-223 may be involved in the
development of osteosarcoma by accelerating cell invasion. Fur-
thermore, serum miR-223 could be potentially explored as a novel
and efﬁcient prognostic biomarker osteosarcoma in order to im-
prove personalized therapeutic strategies.
Conﬂict of interest
None.
Fig. 3. (A) miR-223 mimics signiﬁcantly inhibited the migration of HOS and MG-63 cells (*Po0.05) compared to native HOS and MG-63 cells and negative control cells.
(B) miR-223 mimics signiﬁcantly reduced the invasion of HOS and MG-63 cells. The results are presented as the relative cell invasion rate (%) compared to native and
negative control cells (Po0.001).
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